Abstract

COJ Reviews & Research

In vivo Evaluation of Serum Biomarkers after Administration of the Biofield Energy Treated Novel Proprietary Test Formulation on L-NAME and High Fat Diet (HFD)-Induced Cardiovascular Disorders in Sprague Dawley Rats

Submission: June 23, 2021; Published: July 08, 2021

DOI: 10.31031/COJRR.2021.03.000558

ISSN: 2639-0590
Volume3 Issue2

Abstract

The present study evaluated cardiovascular health biomarkers from serum after treatment with the Biofield Energy Treated/Blessed novel Proprietary Test Formulation and Biofield Energy Treatment per se to the animals on NG-Nitro-L-Arginine Methyl Ester Hydrochloride (L-NAME) and High Fat Diet (HFD)- induced cardiovascular model in Sprague Dawley rats using various functional serum biomarkers such as Nitric Oxide (NO), angiotensin-II, homocysteine, adiponectin, Apolipoprotein A1 (APO-A1), and Apo B100 (Protein of LDL) using ELISA assay. The test formulation was formulated including minerals (magnesium, zinc, copper, calcium, selenium, and iron), vitamins (ascorbic acid, pyridoxine HCl, vitamin B9, vitamin B12, and vitamin D3), Cannabidiol (CBD) isolate, Panax ginseng extract, and β-carotene. The constituents of the test formulation were divided into two parts; one part was referred as the untreated test formulation, while the other part and three group of animals received Biofield Energy Healing Treatment/Blessing remotely for about 3 minutes by a renowned spiritual healing expert, Mr. Mahendra Kumar Trivedi. Serum NO was found to be decreased by 12.1%, 22.1%, 25.3%, 28.3%, and 29.1% in the G5 (L-NAME+HFD + the Biofield Energy Treated test formulation), G6 (L-NAME + HFD + Biofield Energy Treatment per se to animals from day -15), G7 (L-NAME+HFD + the Biofield Energy Treated/Blessed test formulation from day -15), G8 (L-NAME+HFD + Biofield Energy Treatment/Blessing per se plus the Biofield Energy Treated/Blessed test formulation from day -15), and G9 (L-NAME+HFD + Biofield Energy Treatment per se animals plus the untreated test formulation) groups, respectively, as compared to the disease control G2 group. However, serum NO was decreased by 9.9% and 10.9% in the G8 and G9 groups, respectively than untreated test formulation (G4) group. In addition, serum angiotensin-II level was significantly decreased by 14.1% in the G6 group as compared to the G4 group. Similarly, the homocysteine level was significantly decreased by 56.36%, 47.84%, 45.93%, 54.85%, and 53.79% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G2. Adiponectin level was increased by 34.97%, 25.15%, 46.01%, 22.70%, and 38.24% in the G5, G6, G7, G8, and G9 groups, respectively as compared to the G4 group. APO-A1 level in the G7 group showed increased APO-A1 by 13.5% and 10.4% as compared to the G2 and G4 group, respectively. Apo-B100 was significantly decreased by 12.5%, and 13.8% in the G7 and G9 groups, respectively than G4 group. Thus, all serum biomarkers defined as improved tested parameters after treatment with Biofield Energy Treated test formulation and Biofield Energy Treatment per se along with preventive measure on the animals, which could be beneficial against many cardiovascular disorders. Therefore, the results showed the significant reduced antioxidant level, reduced stress-related cardiovascular disease progression and its complications/symptoms such as Ischaemia, myocardial infarction, cardiac and vascular protection, cardiovascular risk factor, stroke, peripheral vessel diseases, and pulmonary embolism, and many cardiovascular health diseases. Biofield Energy Treatment/Blessing might act as a preventive maintenance therapy to maintain good health, to fully restore health, or to improve the overall health and quality of human life.

Keywords: Biofield treatment; Cardiovascular disorders; Myocardial infarction; Adiponectin; Apolipoprotein; The Trivedi effect®; ELISA; High fat diet

Get access to the full text of this article